297P - Real-world data on prognostication of early stage breast cancer patients using CanAssist Breast- first immunohistochemistry based prognostic test developed and validated on Asians

Background

Data on prognostication of Asian HR+/HER2- early stage breast cancer patients using Western prognostic tests is limited and intriguing. Asian patients do get diagnosed almost a decade earlier and typically with slightly increased tumor burden than seen in the west, thus the underlying tumor biology could be different. CanAssist Breast (CAB)- an immunohistochemistry (IHC) and ML based prognostic test, was developed on Indian patient’s tumors to ensure Asian patient’s tumor biology is well represented. CAB has been validated in retrospective global studies in India, US, Spain, Germany, Austria, Italy and in prospective randomised completed TEAM trial in The Netherlands. CAB is able to segregate pre-and post menopausal patients, clinically low and high risk patients in CAB low and high risk categories statistically significantly. Since mid 2016, CAB has been in clinical use in South East Asia, Türkiye, UAE.

Methods

We analysed CAB user data over last ∼8 years (from 2016 mid to December 2023) to understand the details of patients who have used CAB to plan treatment, specifically, we looked at age, stage of breast cancer, etc to assess real world performance of CAB.

Results

CAB has been prescribed on ∼5000 HR+/HER2- breast cancer patients in this time period and sales are increasing yearly. Overall, 73% of the total patients are over 50 years of age, 63% with T2, 65% with Grade 2 tumors and 82% with N0 disease. Median age of patients and tumor size have been 58 years and 2.5 cms respectively. T2N0 ie Stage 2A is most represented (51%) while T1N1 and T2N1 together account for ∼20%. Overall, 74% patients have been stratified as ‘low-risk’ for breast cancer recurrence. Majority of the patients have been from private hospitals thus leading to significant savings of the chemotherapy and associated side effect management costs.

Conclusions

CAB is first of its kind prognostic test developed and validated on Asian patients. The increase in prescriptions shows confidence of clinicians in CAB. CAB represents tumor biology of younger patients and coupled with world-wide validation it presents as a cost-effective, ideal alternative to western prognostic tests for patients in Asia, Africa and ME.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

OncoStem Diagnostics Pvt Ltd.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.